This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine/metabolic disease				
Diabetes	Fibroblast growth factor 1 (FGF1)	<p>Mouse studies suggest recombinant FGF1 could help treat type 2 diabetes. In mouse models of genetic or diet-induced obesity, a single subcutaneous dose of recombinant mouse Fgf1 decreased glucose levels compared with saline without causing hypoglycemia. In these mouse models, chronic treatment decreased blood glucose levels and increased insulin sensitivity compared with saline and did not cause side effects associated with insulin-sensitizing therapeutics such as weight gain and bone loss. Next steps include testing recombinant FGF1 in large animal models of diabetes.</p> <p>SciBX 7(31); doi:10.1038/scibx.2014.922 Published online Aug. 14, 2014</p>	Patent applications filed; available for licensing	<p>Suh, J.M. <i>et al. Nature</i>; published online July 16, 2014; doi:10.1038/nature13540 Contact: Ronald M. Evans, Salk Institute for Biological Studies, La Jolla, Calif. e-mail: evans@salk.edu</p>